 |
SV Life Sciences Fund IIISVLSF III closed in 2003 with total commitments of $393 million (plus $8 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010 the Fund had invested $374 million in 39 portfolio companies. To go to individual portfolio companies websites please click on company logo. Medical Devices / Instrumentation
AqueSys: US
First investment: 2006 - Early Stage AqueSys is based in Duluth, GA; AqueSys (TIF company) is developing an innovative approach to reducing intra-ocular pressure to treat glaucoma. 
Cellutions: US - Exited
First investment: 2004 - Seed Cellutions is based in Duluth, GA, (TIF)is developing a minimally invasive approach for addressing cellulite and its appearance on the skin. 
CHF Solutions: US
First investment: 2005 - Expansion CHF is based in Brooklyn Park, MN and has developed a mechanical pump/filter system to remove excess fluid from patients with acute de-compensated congestive heart failure. The product has US 510k clearance and is CE marked for both in-patient hospital care and out-patient clinic use. 
Concentric Medical: US
First investment: 2003 - Expansion Concentric is based in Mountain View, CA. Designing and developing products to open the pathway for stroke treatment. Their first device, the MERCI Retriever, removes clots associated with ischemic strokes. 
EBR Systems: US
First investment: 2005 - Early Stage EBR Systems is developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure. 
Entellus: US
First investment: 2006 - Early Stage Entellus is a company developing medical device therapies for nasal and sinus disease. 
Eunoe: US - Exited
First investment: 2003 - Expansion Eunoe was a treatment of neurological disorders through cerebrospinal fluid management (CSF). 
Gyros: Sweden - Exited
First investment: 2002 - Start Up Gyros, located in Uppsala, Sweden, has developed a proprietary microfluidics technology for processing and analysis of proteins and blood samples. Laboratory processes are integrated into a client specific disc (CD) format. The CD is processed and its contents analysed on software controlled instrumentation. 
Insulet: US - Exited
First investment SVLSF III: 2004 - Late Stage Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump. 
LipoSonix: US - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting. Funded through the innovation factory. 
NeoVista: US
First investment: 2003 - Seed NeoVista based in Fremont, CA, is developing a surgical device for controlled irradiation to target tissue for arresting the progression of neovascularization, the cause of Wet AMD. 
NovaLign: US
First investment: 2005 - Seed NovaLign based in Duluth, GA; is developing a minimally invasive implant for long bone fixation. Formerly know as OsteoLign. 
ReShape: US
First investment: 2005 - Seed ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity. 
Sadra Medical: US
First investment: 2003 - Seed Sadra based in Campbell, CA, is developing an innovative new approach to aortic valve disease through a minimally invasive percutaneous replacement solution. 
Spinal Kinetics: US
First investment: 2005 - Early Stage Spinal Kinetics based in Redwood City, CA, is developing a 3rd generation artificial disc for cervical and lumbar spine surgery as an alternative to fusion. 
| |
